VALN Stock — Valneva SE: Cash, EV, Pipeline

Share price

$6.56

Market cap

$622.4M

Cash

$128.8M

Enterprise value

$700.3M

Balance sheet

Cash	$128.8M
Debt	$206.7M
Net cash	-$77.9M
Enterprise value	$700.3M
Basic shares	94.9M shares
Fully diluted shares	86.3M shares
Fully diluted market cap	$566.0M
Cash per share	$1.36

Cash figures as of 2025-12-31. Database snapshot: 2026-09-21.

Price history

Loading VALN daily closes…

Loading price history…

Pipeline assets

VLA15

Phase 3 · Active Modality: vaccine

Target Borrelia burgdorferi

Partnerships Pfizer: conducts VALOR Phase 3; sole discretion over regulatory submissions, marketing, and commercialization; milestone and royalty revenue expected

Indications

Lyme disease (Phase 3)

Catalysts

— H1 2026
— 2026
— 2027 or 2028

Status note Pivotal placebo-controlled efficacy trial (VALOR) conducted by Pfizer. Company plans restructuring/cost containment if primary endpoints not met.

VLA1553

Approved · Active Modality: vaccine

Aliases IXCHIQ

Target Chikungunya virus

Partnerships Instituto Butantan: manufacturing/commercialization in low- and middle-income countries; Serum Institute of India agreement terminated end 2025 (seeking new Asia partner for manufacturing/marketing/distribution)

Indications

Chikungunya (Stage not disclosed)

Status note 2025 sales below expectations following reports of serious adverse events and subsequent regulatory action. Pursuing approvals in additional markets.

S4V2

Phase 2 · Active Modality: vaccine

Target Shigella

Indications

Shigellosis (Phase 2)

Status note Ongoing Phase 2 trials.

Per-asset detail extracted from the 20-F filed 2026-03-17. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Frazier Life Sciences	2,291,666	no change	0.26%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

VALN — Valneva SE

Balance sheet

Price history

Pipeline assets

Institutional holders